Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Aldeyra Therapeutics reports positive milestones and financial stability in Q4 2022

Aldeyra Therapeutics showcased positive performance in key milestones, financial stability, and progress in clinical studies, positioning the company for future growth.
Despite challenges in managing expenses and meeting enrollment deadlines, Aldeyra's strengths in its pipeline and financial position offer opportunities for success.
The upcoming year holds promise for Aldeyra with novel therapies addressing unmet medical needs and significant milestones expected in key trials.
Overall, Aldeyra's focus on advancing treatments for ocular and systemic conditions underscores its commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) securities between March 17, 2022 and June 20, 2023, inclusive (the “Class Period”). Aldeyra investors have until September 29, 2023 to file a lead plaintiff motion. Investors suffering losses on their Aldeyra investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors

LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and June 20, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 29, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Aug. 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ALDX INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Aldeyra investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) investors concerning the Company's possible violations of federal securities laws. On June 21, 2023, Aldeyra disclosed that it had received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) regarding the Company's New Drug Application (“NDA”) for its vitreoretinal lymphoma treatment, ADX-2191. Th.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 21, 2023, Alderya disclosed that it had received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) regarding the Company's New Dru.

The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 29, 2023. SO WHAT: If you purchased Aldeyra securities during the.

EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX

SAN DIEGO--(BUSINESS WIRE)---- $ALDX #ALDX--Alderya Therapeutics, Inc. (ALDX) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)

The mean of analysts' price targets for Aldeyra Therapeutics, Inc. (ALDX) points to a 107.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).   Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The company's drug, reproxalap, is under FDA review for treating dry eye disease, with a decision expected in November 2023. Despite potential regulatory, market acceptance, financial, competition, and legal risks, Aldeyra Therapeutics is seen as a potential 'Buy' opportunity for long-term investors.

Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the SVB Securities Therapeutics Forum. The Forum will be held July 11-12, 2023, in New York City. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering in.

Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum

LEXINGTON, Mass.--(BUSINESS WIRE)---- $aldx #adx2191--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from the Phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa. Relative to baseline, the clinical trial demonstrated statistically significant.

Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 29, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑2191 in patients with retinitis pigmentosa. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be acces.

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from the Phase 2 clinical trial of orally administered ADX‑629, an investigational new drug, in patients with chronic cough. The clinical trial demonstrated statistically significant reduction in cough frequency following administration of AD.

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑629 in patients with chronic cough. The dial-in numbers are (888) 415‑4305 for domestic callers and (646) 960‑0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible fro.

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough

LEXINGTON, Mass.--(BUSINESS WIRE)--(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000® and the Russell 3000® indexes, effective after the U.S. equity markets close on June 23, 2023. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28 2023, ranking them by total market capitalization, including both t.

Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.

Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL). Although no safety or.

Aldeyra Therapeutics Provides Regulatory Update on ADX-2191

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.

Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study

Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease that provides immediate relief to patients. The trial results showed statistically significant improvements in allergic conjunctivitis and complements existing NDA for dry eye disease. With probable approval likely for both dry eye disease and allergic conjunctivitis, Reproxalap will be the subject of great pharma interest.

Aldeyra's Stellar Allergic Conjunctivitis Results To Raise Reproxalap Monetization Value

Aldeyra Therapeutics Inc (NASDAQ:ALDX) is up 14.1% at $11.93 at last glance, after the biotech's allergy treatment in the form of liquid eye drops, reproxalap, met its goal in a late-stage study.

Biotech Stock Surges on Eye Treatment Study

Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic conjunctivitis has achieved statistical significance for the primary endpoint of ocular itching and all secondary endpoints in a Phase 3 clinical trial, sending the company's stock soaring. “Consistent with the results of the Phase 3 INVIGORATE Trial and in conjunction with a number of successful Phase 2 and Phase 3 clinical trials in dry eye disease, achievement of the primary endpoint and all secondary endpoints in INVIGORATE-2 supports the potential of reproxalap as a treatment for inflammatory diseases of the ocular surface,” said Aldeyra CEO Dr. Todd Brady.

Aldeyra Therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint

Aldeyra Therapeutics said on Thursday its experimental drug to treat an inflammatory eye disease met the main goal of reducing itching in a late-stage study.

Aldeyra Therapeutics eye treatment meets late-stage study main goal

Aldeyra Therapeutics Inc.'s stock ALDX, +0.63% jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of a treatment for allergic conjunctivitis. The Lexington, Mass.

News for Aldeyra Therapeutics Stock (ALDX)